Acura Pharmaceuticals advances LTX-04 and its LIMITx(TM) technology
Acura Pharma announced the results from its second clinical study, study AP-LTX-401. Study 401 demonstrate that the maximum plasma level of drug following oral excessive tablet abuse of the early development stage product LTX-04P3 are reduced by up to 65% compared to currently marketed products. June 28, 2017